Multi-Modality Therapy Archives | Surviving Mesothelioma

New Chemotherapy Booster May Extend Mesothelioma Survival

Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival »

New Report Reveals Disparities in Mesothelioma Treatment

A new study of mesothelioma treatment and survival in the US contains some disturbing facts about treatment trends. Among them is the fact that people over 70 are much less likely to get any treatment for malignant mesothelioma, a rare but but fast-growing malignancy that can be quickly fatal. In fact, nearly a third of mesothelioma patients receive no therapy at all. The study was … Continue reading New Report Reveals Disparities in Mesothelioma Treatment »

10-Year Study Confirms Longer Mesothelioma Survival with Trimodal Therapy

Surgery for Peritoneal Mesothelioma

Trimodality therapy including surgery, chemotherapy, and radiation appears to give carefully-selected patients the best odds of surviving mesothelioma. In a new article in the Journal of Clinical Oncology, researchers from MD Anderson Cancer Center detail the results of their analysis of mesothelioma survival using the National Cancer Database. Long-Term Mesothelioma Research The research team started with a pool of 20,561 pleural mesothelioma cases diagnosed between … Continue reading 10-Year Study Confirms Longer Mesothelioma Survival with Trimodal Therapy »

Long-Term Peritoneal Mesothelioma Survival with Apitolisib

There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib. Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. According to the National Cancer Institute, the one-year survival rates for … Continue reading Long-Term Peritoneal Mesothelioma Survival with Apitolisib »

IMRT “Feasible and Effective” for Pleural Mesothelioma

When malignant pleural mesothelioma patients receive radiation therapy in the form of IMRT (intensity modulated radiation therapy) at an experienced institution, the treatment can be both feasible and effective. That is the conclusion of Dr. Kenneth Rosenzweig, Chairman of the Department of Radiation Oncology at Mount Sinai School of Medicine in New York. Rosenzweig is the author of a new summary of radiation therapy in … Continue reading IMRT “Feasible and Effective” for Pleural Mesothelioma »

Study to Test New Three-Drug Treatment for Pleural Mesothelioma

The makers of a VEGF-inhibitor called nintedanib are recruiting patients with unresectable pleural mesothelioma for a Phase III clinical trial of the drug in combination with standard chemotherapy. The multicenter trial sponsored by drug maker Boehringer Ingelheim will eventually include a total of 450 mesothelioma patients, but preliminary results from the first 87 patients look promising.  According to data presented at the 2017 American Society of Clinical Oncology … Continue reading Study to Test New Three-Drug Treatment for Pleural Mesothelioma »

Boosting Mesothelioma Survival with VEGF-Inhibitor

The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor »

Cholesterol Drug May Protect Mesothelioma Patients from Radiation

A new study suggests that the cholesterol-lowering drug pravastatin could one-day be used to help protect mesothelioma patients from the damaging side effects of radiotherapy. According to Japanese researchers, mice with malignant mesothelioma who were given pravastatin (Pravachol) in drinking water prior to receiving radiation experienced less damage to healthy cells in their lungs and intestines. The results suggest that pravastatin might make radiotherapy safer … Continue reading Cholesterol Drug May Protect Mesothelioma Patients from Radiation »

Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma

Viruses may soon be playing a bigger role in the fight against malignant mesothelioma and other thoracic cancers. A pair of biologists from Minnesota say there is evidence that, in addition to killing mesothelioma cells directly, specific kinds of altered viruses might help make mesothelioma immunotherapy treatment more effective. How Does Immunotherapy Work? Like many other types of cancer, mesothelioma tumors are able to grow unchecked … Continue reading Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma »

Standardization Needed for Peritoneal Mesothelioma Treatment

Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment »

Get your free copy of
“Surviving Mesothelioma” Today!